|
1
|
Sherief AM, Elsafy UR, Abdelkhalek ER,
Kamal NM, Youssef DM and Elbehedy R: Disease patterns of pediatric
non-Hodgkin lymphoma: A study from a developing area in Egypt. Mol
Clin Oncol. 3:139–144. 2015.
|
|
2
|
Bradley WD, Arora S, Busby J,
Balasubramanian S, Gehling VS, Nasveschuk CG, Vaswani RG, Yuan CC,
Hatton C, Zhao F, et al: EZH2 inhibitor efficacy in non-Hodgkin's
lymphoma does not require suppression of H3K27 monomethylation.
Chem Biol. 21:1463–1475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyazaki T, Atarashi Y, Yasumura S,
Minatoya I, Ogawa K, Iwamoto M, Minemura M, Shimizu Y, Sato TA,
Watanabe A, et al: Fas-associated phosphatase-1 promotes
Fas-mediated apoptosis in human colon cancer cells: Novel function
of FAP-1. J Gastroenterol Hepatol. 21:84–91. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yeh SH, Wu DC, Tsai CY, Kuo TJ, Yu WC,
Chang YS, Chen CL, Chang CF, Chen DS and Chen PJ: Genetic
characterization of fas-associated phosphatase-1 as a putative
tumor suppressor gene on chromosome 4q21.3 in hepatocellular
carcinoma. Clin Cancer Res. 12:1097–1108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eberth S, Schneider B, Rosenwald A,
Hartmann EM, Romani J, Zaborski M, Siebert R, Drexler HG and
Quentmeier H: Epigenetic regulation of CD44 in Hodgkin and
non-Hodgkin lymphoma. BMC Cancer. 10:5172010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abaan OD and Toretsky JA: PTPL1: A large
phosphatase with a split personality. Cancer Metastasis Rev.
27:205–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo H, Zhu P, Yan L, Li R, Hu B, Lian Y,
Yan J, Ren X, Lin S, Li J, et al: The DNA methylation landscape of
human early embryos. Nature. 511:606–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lübbert M: DNA methylation inhibitors in
the treatment of leukemias, myelodysplastic syndromes and
hemoglobinopathies: Clinical results and possible mechanisms of
action. Curr Top Microbiol Immunol. 249:135–164. 2000.PubMed/NCBI
|
|
9
|
Amara K, Ziadi S, Hachana M, Soltani N,
Korbi S and Trimeche M: DNA methyltransferase DNMT3b protein
over-expression as a prognostic factor in patients with diffuse
large B-cell lymphomas. Cancer Sci. 101:1722–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bejar R and Steensma DP: Recent
developments in myelodys-plastic syndromes. Blood. 124:2793–2803.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Freiss G and Chalbos D: PTPN13/PTPL1: An
important regulator of tumor aggressiveness. Anticancer Agents Med
Chem. 11:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi H, Guo J, Duff DJ, Rahmatpanah F,
Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski
M, Wooldridge JE, et al: Discovery of novel epigenetic markers in
non-Hodgkin's lymphoma. Carcinogenesis. 28:60–70. 2007. View Article : Google Scholar
|
|
14
|
Lossos IS: The DNA methylome: A novel
biomarker. Blood. 123:1627–1628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bittenbring JT, Neumann F, Altmann B,
Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G and
Pfreundschuh M: Vitamin D deficiency impairs rituximab-mediated
cellular cytotoxicity and outcome of patients with diffuse large
B-cell lymphoma treated with but not without rituximab. J Clin
Oncol. 32:3242–3248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hunter T: The role of tyrosine
phosphorylation in cell growth and disease. Harvey Lect. 94:81–119.
1998–1999.PubMed/NCBI
|
|
17
|
Paz MF, Fraga MF, Avila S, Guo M, Pollan
M, Herman JG and Esteller M: A systematic profile of DNA
methylation in human cancer cell lines. Cancer Res. 63:1114–1121.
2003.PubMed/NCBI
|
|
18
|
Bodoor K, Haddad Y, Alkhateeb A, Al-Abbadi
A, Dowairi M, Magableh A, Bsoul N and Ghabkari A: DNA
hypermethylation of cell cycle (p15 and p16) and apoptotic (p14,
p53, DAPK and TMS1) genes in peripheral blood of leukemia patients.
Asian Pac J Cancer Prev. 15:75–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kupčinskaitė-Noreikienė R, Skiecevičienė
J, Jonaitis L, Ugenskienė R, Kupčinskas J, Markelis R, Baltrėnas V,
Sakavičius L, Semakina I, Grižas S, et al: CpG island methylation
of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent
noncancerous stomach tissues. Medicina (Kaunas). 49:361–366.
2013.
|
|
20
|
Ng HY, Wan TS, So CC and Chim CS:
Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in
acute promyelocytic leukaemia. J Clin Pathol. 67:626–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hutt DM, Roth DM, Vignaud H, Cullin C and
Bouchecareilh M: The histone deacetylase inhibitor, Vorinostat,
represses hypoxia inducible factor 1 alpha expression through
translational inhibition. PLoS One. 9:e1062242014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Witzig TE, Hu G, Offer SM, Wellik LE, Han
JJ, Stenson MJ, Dogan A, Diasio RB and Gupta M: Epigenetic
mechanisms of protein tyrosine phosphatase 6 suppression in diffuse
large B-cell lymphoma: Implications for epigenetic therapy.
Leukemia. 28:147–154. 2014. View Article : Google Scholar :
|
|
23
|
Kroesen M, Gielen P, Brok IC, Armandari I,
Hoogerbrugge PM and Adema GJ: HDAC inhibitors and immunotherapy; a
double edged sword? Oncotarget. 5:6558–6572. 2014.PubMed/NCBI
|
|
24
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
25
|
Jones PA: Overview of cancer epigenetics.
Semin Hematol. 42(Suppl 2): S3–S8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ying J, Li H, Cui Y, Wong AH, Langford C
and Tao Q: Epigenetic disruption of two proapoptotic genes
MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas
through hypermethylation of a common bidirectional promoter.
Leukemia. 20:1173–1175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee SH, Shin MS, Lee HS, Bae JH, Lee HK,
Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, et al: Expression of Fas
and Fas-related molecules in human hepatocellular carcinoma. Hum
Pathol. 32:250–256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sripayap P, Nagai T, Uesawa M, Kobayashi
H, Tsukahara T, Ohmine K, Muroi K and Ozawa K: Mechanisms of
resistance to azacitidine in human leukemia cell lines. Exp
Hematol. 42:294–306. 2014. View Article : Google Scholar
|
|
29
|
Zhou Y and Hu Z: Genome-wide demethylation
by 5-aza-2′-de-oxycytidine alters the cell fate of stem/progenitor
cells. Stem Cell Rev. 11:87–95. 2015. View Article : Google Scholar
|
|
30
|
Chaudhry P, Srinivasan R and Patel FD:
Differential expression of Fas family members and Bcl-2 family
members in benign versus malignant epithelial ovarian cancer (EOC)
in North Indian population. Mol Cell Biochem. 368:119–126. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mori S, Murakami-Mori K, Jewett A,
Nakamura S and Bonavida B: Resistance of AIDS-associated Kaposi's
sarcoma cells to Fas-mediated apoptosis. Cancer Res. 56:1874–1879.
1996.PubMed/NCBI
|
|
32
|
Zhang X, Brunner T, Carter L, Dutton RW,
Rogers P, Bradley L, Sato T, Reed JC, Green D and Swain SL: Unequal
death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2,
effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med.
185:1837–1849. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nariai Y, Mishima K, Yoshimura Y and
Sekine J: FAP-1 and NF- κB expressions in oral squamous cell
carcinoma as potential markers for chemo-radio sensitivity and
prognosis. Int J Oral Maxillofac Surg. 40:419–426. 2011. View Article : Google Scholar
|
|
34
|
Vondrácek J, Sheard MA, Krejcí P, Minksová
K, Hofmanová J and Kozubík A: Modulation of death receptor-mediated
apoptosis in differentiating human myeloid leukemia HL-60 cells. J
Leukoc Biol. 69:794–802. 2001.PubMed/NCBI
|
|
35
|
Michor F, Hughes TP, Iwasa Y, Branford S,
Shah NP, Sawyers CL and Nowak MA: Dynamics of chronic myeloid
leukaemia. Nature. 435:1267–1270. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Arai M, Kannagi M, Matsuoka M, Sato T,
Yamamoto N and Fujii M: Expression of FAP-1 (Fas-associated
phosphatase) and resistance to Fas-mediated apoptosis in T cell
lines derived from human T cell leukemia virus type 1-associated
myelopathy/tropical spastic paraparesis patients. AIDS Res Hum
Retroviruses. 14:261–267. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Glondu-Lassis M, Dromard M, Lacroix-Triki
M, Nirdé P, Puech C, Knani D, Chalbos D and Freiss G: PTPL1/PTPN13
regulates breast cancer cell aggressiveness through direct
inactivation of Src kinase. Cancer Res. 70:5116–5126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He RJ, Yu ZH, Zhang RY and Zhang ZY:
Protein tyrosine phosphatases as potential therapeutic targets.
Acta Pharmacol Sin. 35:1227–1246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kamihira S, Yamada Y, Hirakata Y, Tomonaga
M, Sugahara K, Hayashi T, Dateki N, Harasawa H and Nakayama K:
Aberrant expression of caspase cascade regulatory genes in adult
T-cell leukaemia: Survivin is an important determinant for
prognosis. Br J Haematol. 114:63–69. 2001. View Article : Google Scholar : PubMed/NCBI
|
